27374-25-0,CAS 27374-25-0

製品名:(1-ethoxycyclopropoxy)trimethylsilane

IUPAC Name:(1-ethoxycyclopropoxy)trimethylsilane

包装単位	有効在庫	価格（USD）
CM111264-10g	in stock	Ōƚƿ
CM111264-50g	in stock	ŤŮŮ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 27374-25-0 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:27374-25-0; 分子式:C8H18O2Si; 融点:-; SMILESコード:C[Si](C)(OC1(OCC)CC1)C; 密度:

: カタログ番号:CM111264; 分子量:174.32; 沸点:; MDL番号:MFCD00074986; 保管方法:

: Cyclopropanes; Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

: Silane Compounds; Silanes are a series of silicon substitutes for carbon alkanes, which consisting of multiple silicon atoms linked to each other as the main chain and hydrogen atoms or other chemical elements linked with the main chain. Silanes are versatile chemicals used in the modification of SPR sensor surfaces. In particular, the silane molecules, such as 3-mercaptopropyl trimethoxy silane, are convenient for use as linkers in surface modification of SPR sensors.

: JNT-517; Jnana Therapeutics announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all ages and genotypes. Based on these positive mid-term results, Jnana has adjusted its phase 1b clinical trial design to support the critical phase 3 clinical trial of JNT-517 starting in the first half of 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.